Bartlett & CO. Wealth Management LLC Grows Holdings in Checkpoint Therapeutics, Inc. (NASDAQ:CKPT)

Bartlett & CO. Wealth Management LLC raised its position in Checkpoint Therapeutics, Inc. (NASDAQ:CKPT) by 375.0% during the fourth quarter, Holdings Channel.com reports. The firm owned 19,000 shares of the company’s stock after buying an additional 15,000 shares during the period. Bartlett & CO. Wealth Management LLC’s holdings in Checkpoint Therapeutics were worth $61,000 at the end of the most recent quarter.

Other institutional investors and hedge funds also recently added to or reduced their stakes in the company. Virtu Financial LLC acquired a new position in shares of Checkpoint Therapeutics during the 3rd quarter valued at about $30,000. XTX Topco Ltd acquired a new position in shares of Checkpoint Therapeutics during the 2nd quarter valued at about $34,000. Gladstone Institutional Advisory LLC increased its stake in shares of Checkpoint Therapeutics by 141.4% during the 3rd quarter. Gladstone Institutional Advisory LLC now owns 35,000 shares of the company’s stock valued at $78,000 after acquiring an additional 20,500 shares during the last quarter. Magnus Financial Group LLC increased its stake in shares of Checkpoint Therapeutics by 12.9% during the 3rd quarter. Magnus Financial Group LLC now owns 35,000 shares of the company’s stock valued at $78,000 after acquiring an additional 4,000 shares during the last quarter. Finally, Walleye Capital LLC acquired a new position in shares of Checkpoint Therapeutics during the 3rd quarter valued at about $148,000. 22.00% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

A number of research analysts have recently commented on the stock. HC Wainwright reaffirmed a “buy” rating and set a $20.00 price objective on shares of Checkpoint Therapeutics in a research note on Monday, December 16th. Lake Street Capital upped their price objective on shares of Checkpoint Therapeutics from $4.00 to $7.00 and gave the company a “buy” rating in a research note on Monday, December 16th. Finally, D. Boral Capital started coverage on shares of Checkpoint Therapeutics in a research note on Monday, January 13th. They set a “buy” rating and a $9.00 price objective for the company.

Checkpoint Therapeutics Stock Performance

CKPT opened at $3.00 on Friday. The firm has a 50 day moving average price of $3.57 and a 200 day moving average price of $2.93. The company has a market cap of $146.49 million, a PE ratio of -1.63 and a beta of 1.36. Checkpoint Therapeutics, Inc. has a 1 year low of $1.38 and a 1 year high of $4.50.

Checkpoint Therapeutics (NASDAQ:CKPT) last posted its earnings results on Tuesday, November 12th. The company reported ($0.23) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.15) by ($0.08). On average, sell-side analysts predict that Checkpoint Therapeutics, Inc. will post -0.91 earnings per share for the current year.

Insider Buying and Selling

In other news, CFO William Garrett Gray sold 268,432 shares of the stock in a transaction that occurred on Wednesday, December 18th. The stock was sold at an average price of $4.01, for a total transaction of $1,076,412.32. Following the completion of the transaction, the chief financial officer now directly owns 1,032,754 shares in the company, valued at approximately $4,141,343.54. This represents a 20.63 % decrease in their position. The transaction was disclosed in a filing with the SEC, which can be accessed through this hyperlink. Also, CEO James F. Oliviero III sold 220,230 shares of the stock in a transaction that occurred on Thursday, December 19th. The shares were sold at an average price of $3.38, for a total value of $744,377.40. Following the transaction, the chief executive officer now owns 3,194,583 shares of the company’s stock, valued at approximately $10,797,690.54. This trade represents a 6.45 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Corporate insiders own 2.10% of the company’s stock.

About Checkpoint Therapeutics

Checkpoint Therapeutics, Inc, a clinical-stage immunotherapy and targeted oncology company, focuses on the acquisition, development, and commercialization of novel treatments for patients with solid tumor cancers in the United States and internationally. The company's lead antibody product candidate is Cosibelimab, which is in Phase 1 clinical trial to treat patients with selected recurrent or metastatic cancers; and CK-302, a product candidate in preclinical trials for hematological malignancies and solid tumors.